Novartis
Quick Facts: Novartis
- Signal Score
- 85.4/100 (as of 2026-11-02)
- Quality Compliance
- 97.4/100 — Clean EMA record: 50 active GMP certificates (no deductions)
- Headquarters
- Basel, Switzerland
- Modalities
- CAR-T, Gene Therapy
- Active Programs
- 421 confirmed from ClinicalTrials.gov across 118 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Novartis
Kymriah manufacturer.
Signal Score & Pillar Breakdown
Novartis FDA Inspection History
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2026-06-24 |
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey
Company-level
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
| 2025-12-18 |
Novartis Pharma AG
Basel Town
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2025-12-09 |
Novartis d.o.o.
Ljubljana
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2025-06-25 |
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey
Company-level
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
| 2025-03-03 |
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey
Company-level
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2024-11-19 |
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey
Company-level
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
| 2024-08-29 |
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey
Company-level
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
| 2024-08-08 |
Novartis Pharmaceuticals Corporation
Morris Plains, New Jersey
Company-level
|
Human Cellular, Tissue, and Gene Therapies | Yes | Voluntary Action Indicated (VAI) |
| 2024-06-27 |
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey
Company-level
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
| 2024-06-04 |
Novartis Pharma AG
Basel
Company-level
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
| 2024-02-09 |
Novartis d.o.o.
Ljubljana
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2023-08-21 |
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey
Company-level
|
Bioresearch Monitoring | Yes | Voluntary Action Indicated (VAI) |
| 2023-06-13 |
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey
Company-level
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
| 2023-01-25 |
Novartis d.o.o.
Ljubljana
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2022-12-09 |
Novartis Pharmaceuticals Corporation
Morris Plains, New Jersey
Company-level
|
Human Cellular, Tissue, and Gene Therapies | Not posted | Voluntary Action Indicated (VAI) |
| 2022-09-21 |
Novartis d.o.o.
Menges
Company-level
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2022-08-30 |
Novartis Pharma AG
Basel Town
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2025-07-11 |
Novartis Pharmaceuticals S.R.L.
Targu Mures
Company-level
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2023-08-26 |
Novartis Pharmaceuticals S.R.L.
Targu Mures
Company-level
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
Novartis FDA 483 Findings 5 observations · 2023-08-21 → 2024-08-08 ?
By subsystem
By severity
- 5 — Critical: 1
- 3 — Moderate: 1
- 2 — Minor: 3
- Repeat observations: 0
Most severe findings
-
Computer control of master formula records
"Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel."
-
Scientifically sound laboratory controls
"Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, sampling plans and test procedures designed to assure that components, drug product containers, closures, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity."
-
Procedures not in writing, fully followed
"The responsibilities and procedures applicable to the quality control unit are not fully followed."
Novartis EMA GMP Compliance 50 certificates
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| sukls112553/2026 | Novartis s.r.o. | Czechia | 2026-04-15 | COMPLIANT |
| sukls112575/2026 | Novartis s.r.o. | Czechia | 2026-04-14 | COMPLIANT |
| BE/GMP/2026/031 | Novartis ManufacturingAlternative Name:Novartis Manufacturing N.V. | Belgium | 2026-03-18 | COMPLIANT |
| 484341-105007650 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2026-03-17 | COMPLIANT |
| DE_BY_05_GMP_2026_0054 | Novartis Pharma GmbH | Germany | 2026-02-10 | COMPLIANT |
| IT/90/H/2026 | Novartis Farma S.p.A. | Italy | 2026-01-16 | COMPLIANT |
| 450-8/2026-2 | Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. | Slovenia | 2025-12-19 | COMPLIANT |
| 450-15/2026-2 | Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. | Slovenia | 2025-12-19 | COMPLIANT |
| 450-16/2026-2 | Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. | Slovenia | 2025-12-19 | COMPLIANT |
| 25/23121-34 | Novartis Norge AS | Norway | 2025-12-10 | COMPLIANT |
| 401-27/2025-8 | Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. | Slovenia | 2025-12-09 | COMPLIANT |
| 450-15/2026-1 | Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. | Slovenia | 2025-12-09 | COMPLIANT |
| 450-16/2026-1 | Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. | Slovenia | 2025-12-09 | COMPLIANT |
| 484326-105148947 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-12-05 | COMPLIANT |
| 484326-103675833 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-12-05 | COMPLIANT |
| 484296-103675257 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-12-04 | COMPLIANT |
| 484296-105553013 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-12-04 | COMPLIANT |
| 484296-105579653 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-12-04 | COMPLIANT |
| 484296-105654285 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-12-04 | COMPLIANT |
| BE/GMP/2025/157 | Novartis PharmaAlternative Name:Novartis Pharma N.V. | Belgium | 2025-11-24 | COMPLIANT |
| BE/GMP/2025/156 | Novartis PharmaAlternative Name:Novartis Pharma N.V. | Belgium | 2025-11-24 | COMPLIANT |
| BE/GMP/2025/206 | Novartis PharmaAlternative Name:Novartis Pharma N.V. | Belgium | 2025-11-24 | COMPLIANT |
| BE/GMP/2025/207 | Novartis PharmaAlternative Name:Novartis Pharma N.V. | Belgium | 2025-11-24 | COMPLIANT |
| 484600-104544504 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-10-20 | COMPLIANT |
| 484600-105471718 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-10-20 | COMPLIANT |
| DE_BY_05_GMP_2026_0024 | Novartis Pharma GmbH | Germany | 2025-10-14 | COMPLIANT |
| 484295-104642509 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-10-10 | COMPLIANT |
| 484295-103675105 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-10-10 | COMPLIANT |
| 484295-104295901 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-10-10 | COMPLIANT |
| 484295-105471003 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-10-10 | COMPLIANT |
| 484295-105582044 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-10-10 | COMPLIANT |
| 484295-105600304 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-10-10 | COMPLIANT |
| 484295-105619677 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2025-10-10 | COMPLIANT |
| 401-7/2025-5 | Novartis Pharmaceutical Manufacturing LLC | Slovenia | 2025-04-10 | COMPLIANT |
| 450-16/2026-3 | Novartis Pharmaceutical Manufacturing LLC | Slovenia | 2025-04-10 | COMPLIANT |
| 484496-103501763 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2024-11-04 | COMPLIANT |
| 450-4/2025-1 | Novartis Pharmaceutical Manufacturing LLC | Slovenia | 2024-09-20 | COMPLIANT |
| 484295-102362426 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-12-14 | COMPLIANT |
| 484295-104659277 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-12-14 | COMPLIANT |
| 484295-103890257 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-12-14 | COMPLIANT |
| 484295-104484889 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-12-14 | COMPLIANT |
| 484295-102504807 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-12-14 | COMPLIANT |
| 484295-104299099 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-12-14 | COMPLIANT |
| 484295-104466717 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-12-14 | COMPLIANT |
| 484295-104090448 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-12-14 | COMPLIANT |
| 484295-102485983 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-12-14 | COMPLIANT |
| 484295-102771143 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-12-14 | COMPLIANT |
| 484341-101944492 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-06-27 | COMPLIANT |
| 484296-103654468 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-02-15 | COMPLIANT |
| 484326-101544917 | Novartis Pharmaceutical Manufacturing GmbH | Austria | 2023-02-13 | COMPLIANT |
Novartis MHRA GMP Compliance 1 certificates
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK GMP 4647 Insp GMP 4647/1766568-0003[H] | NOVARTIS | 94070-06256 | 2013-04-22 | COMPLIANT |
Japan-accredited overseas site (PMDA)
sterile, biologics, general (non-sterile), packaging/storage only, CGT packaging/storage only · 5 sites · own products, not contract-manufacturing evidence
- Langkampfen, Austria · Novartis Pharmaceutical Manufacturing GmbH — sterile, biologics, packaging/storage only, CGT packaging/storage only · valid to Jun 30, 2028
- Puurs-Sint-Amands, Belgium · Novartis Manufacturing NV — sterile · valid to Oct 27, 2029
- Romania · Novartis Pharmaceuticals S.r.l. — general (non-sterile) · valid to Aug 31, 2030
- Ljubljana, Slovenia · Novartis Pharmaceutical Manufacturing LLC — sterile, general (non-sterile) · valid to Jul 2, 2028
- Menges, Slovenia · Novartis Pharmaceutical Manufacturing LLC — biologics, general (non-sterile) · valid to Jul 2, 2028
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. These approvals cover the company's own products; they are not evidence of contract manufacturing. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)